Perceived Efficacy Of Cannabidiol-enriched Cannabis Extracts For Treatment Of Pediatric Epilepsy: A Potential Role For Infantile Spasms And Lennox-Gastaut Syndrome (LGS)

Epilepsy Lennox-Gastaut syndrome (LGS)

Key Findings

The median duration and the median dosage of CBD exposure were 6.8 months and 4.3mg/kg/day, respectively. Eighty-five percent of all parents reported a reduction in seizure frequency, and 14% reported complete seizure freedom. A high proportion of respondents reported improvement in sleep (53%), alertness (71%), and mood (63%) during CBD therapy. Researchers note: From a methodological standpoint, this study is extraordinarily vulnerable to participation bias and limited by lack of blinded outcome ascertainment. Appropriately controlled clinical trials are essential to establish efficacy and safety.

Information and Links


Link: Perceived Efficacy Of Cannabidiol-enriched Cannabis Extracts For Treatment Of Pediatric Epilepsy: A Potential Role For Infantile Spasms And Lennox-Gastaut Syndrome (LGS)

Year: 2015

DOI: 10.1016/j.yebeh.2015.04.009


Ratings

(How Ratings Work)

Epilepsy — 3


Likely probability of the efficacy of cannabis for treatment of Epilepsy according to the results found in this study.

Lennox-Gastaut syndrome (LGS) — 3


Likely probability of the efficacy of cannabis for treatment of Lennox-Gastaut syndrome (LGS) according to the results found in this study.

Drugs Used

CBD-enriched cannabis preparations